Compound Deep Dive

PT-141 (Bremelanotide): What the Research Actually Shows

The rare research-market peptide with real human trials behind it — and why that cuts both ways.

Introduction

PT-141 occupies a unique position in the peptide world. Unlike almost everything else on the research market — where the evidence lives entirely in rodent studies — PT-141 has completed human clinical trials, and a pharmaceutical formulation of it (bremelanotide, brand name Vyleesi) was approved by the FDA in 2019.

That makes it both the best-documented compound we cover and the one where the gap between "the approved drug" and "the research-market copy" matters most. This article covers the mechanism, the human data, the history — and exactly what a research vial is and is not.

What is PT-141?

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide — seven amino acids in a ring structure: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It is an active metabolite of Melanotan II, the tanning-research peptide; researchers observed that Melanotan II produced unexpected effects on sexual arousal in early studies, isolated the responsible metabolite, and developed it as its own compound.

• Molecular weight: 1025.2 Da
• CAS number: 189691-06-3
• Class: melanocortin receptor agonist (primarily MC4R, with activity at MC3R and MC1R)
• Format in research supply: lyophilized powder, typically 10mg vials

Mechanism of action: what the research shows

PT-141's defining trait is where it acts. Compounds like sildenafil work peripherally — on blood vessels. PT-141 works centrally, on melanocortin receptors in the brain, particularly MC4R in the hypothalamus — circuitry involved in sexual arousal, appetite, and energy balance. In both animal models and human trials, activating this pathway increased measures of sexual desire and arousal independent of vascular mechanics. It is one of the clearest demonstrations in the literature that desire has addressable neurochemistry.

The human data — what makes PT-141 unusual

The RECONNECT trials and FDA approval

Bremelanotide went through full clinical development by Palatin Technologies/AMAG: two Phase 3 randomized, placebo-controlled trials (the RECONNECT studies) in premenopausal women with hypoactive sexual desire disorder (HSDD). Results showed statistically significant improvements in desire scores and distress reduction versus placebo. The FDA approved it in June 2019 as Vyleesi, an on-demand subcutaneous autoinjector. Evidence strength: the real thing — completed human RCTs and a regulatory approval.

Documented human side-effect profile

The same trials give PT-141 something almost nothing else on the research market has: a characterized human side-effect profile. The headline items: nausea (about 40% of trial participants — the most common reason for discontinuation), flushing, headache, injection-site reactions, and a transient increase in blood pressure after dosing (why the label cautions against use in uncontrolled hypertension or cardiovascular disease). An earlier intranasal formulation was abandoned during development specifically over blood-pressure concerns.

Research in men

Bremelanotide was studied in Phase 2 trials for erectile dysfunction in men, with signals of efficacy including in some sildenafil non-responders — but development for that indication was not carried through to approval. The male-use literature is real but incomplete.

What the research does NOT show

• A research-market vial is not Vyleesi. The approved product is a precisely dosed, sterile, pharmaceutical formulation. Gray-market powder has none of those assurances — purity, sterility, and actual content vary by source.
• No approval for men. The ED program stopped at Phase 2; PT-141 is approved only for HSDD in premenopausal women, only as Vyleesi.
• Not studied for "libido enhancement" in healthy people. The trials were in a diagnosed clinical population; there is no evidence base for recreational or wellness use.
• The blood-pressure effect is real. It's in the approved label. Any framing of PT-141 as consequence-free ignores its own trial data.

PT-141 compound profile summary

Sourcing for research: what to look for

Because PT-141 is short and comparatively easy to synthesize, it is one of the more widely available research peptides — which shifts the quality question from "can they make it" to "did they actually verify this batch." A proper CoA should show HPLC purity ≥98% and mass spec confirming ~1025.2 Da (±2 Da). Cyclic peptides can also present truncated linear impurities, so batch-specific documentation matters. Among vendors we've reviewed, PureRx Peptides consistently lists PT-141 and newer compounds at some of the lowest verified prices we've seen — read our full PureRx review and the vendor red-flag guide before buying from anyone.

Frequently asked questions

Is PT-141 the same thing as Vyleesi?

Same molecule, entirely different product. Vyleesi is the FDA-approved, pharmacy-dispensed formulation with regulated manufacturing. Research-market PT-141 is unregulated powder whose actual contents depend entirely on the vendor's honesty and testing.

How is PT-141 related to Melanotan II?

PT-141 is an active metabolite of Melanotan II — the tanning peptide's "accidental discovery." Melanotan II hits melanocortin receptors broadly (including strong MC1R skin-pigmentation effects); PT-141 was developed to focus on the MC4R arousal pathway with less pigmentation activity.

Why does PT-141 cause nausea so often?

Melanocortin receptors also participate in appetite and gut circuits; central MC4R activation appears to drive the nausea seen in ~40% of trial participants. It is the compound's best-documented drawback.

Was PT-141 ever approved for men?

No. Phase 2 ED studies showed promising signals but development for men was discontinued. The only approval is for HSDD in premenopausal women.